Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
- Written by PR Newswire
 |
Highlights:
- NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow
- New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases
- New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson's and...
